Board of Directors

Martyn D. Greenacre has served on the Board since February 2000 and has served as Chairman of the Board since May 2017. From June 1993 to July 2000, he was a director of Creative BioMolecules, Inc., a predecessor life science company of Curis. Mr. Greenacre served as Chairman of Life Mist L.L.C., a privately-held company in the field of fire suppression, from September 2001 to December 2016. From June 1997 to June 2001, he was Chief Executive Officer of Delsys Pharmaceutical Corporation, a drug formulation company. From 1993 to 1997, Mr. Greenacre was President and Chief Executive Officer of Zynaxis, Inc., a biopharmaceutical company. Prior to Zynaxis, Inc., he served in various senior management positions at SmithKline Beecham Limited, a pharmaceuticals company, from 1973 through 1992, including as Chairman of European Operations and was appointed to its Board of Directors. Previously, he served as a director of Acusphere, Inc., Cephalon, Inc., Formula Pharmaceuticals, Neostem, Inc. (now Caladrius, Inc.) and Orchestra Therapeutics, Inc., and as a director and Chairman of BMP Sunstone Corporation. Mr. Greenacre received a B.A. from Harvard College and an M.B.A. from Harvard Business School.

Committee:

Audit
Nominating and Governance

 

---

John Hohneker, M.D., has served on the Board since December 2021. He currently serves on the Board of Directors of ArriVent BioPharma, Inc., Carisma Therapeutics, Inc., Trishula Therapeutics, Inc., and Sonata Therapeutics, Inc. Dr. Hohneker previously served on the Board of Directors of Aravive, Inc., Torque Therapeutics, Inc., Dimension Therapeutics, Inc., Cygnal Therapeutics, Inc., BioTheryX Inc., Evelo Biosciences, and Humanigen, Inc.

Previously, Dr. Hohneker served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company’s transition from a discovery-stage biotech to one with multiple programs in clinical trials. During his tenure at Novartis AG, as SVP and Global Head of Development, Immunology and Dermatology, Dr. Hohneker played a critical role in the development and commercialization of many notable products including Cosentyx^®, Ilaris^®, Gleevec^®, Zometa^®, Tasigna^®, and Afinitor^®. Prior to joining Novartis, he held leadership positions at Glaxo Wellcome and its legacy company, Burroughs Wellcome.

Dr. Hohneker received his bachelor’s degree in chemistry from Gettysburg College and his M.D. from Rutgers School of Biomedical and Health Sciences. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill.

Committee:

Compensation

---

Kenneth I. Kaitin, Ph.D., has served on the Board since November 2003 and is a Senior Fellow at Tufts Center for the Study of Drug Development (“CSDD”), an academic drug policy research group providing strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of the drug development process. From July 1998 to December 2020, Dr. Kaitin served as the Director of Tufts CSDD. Since August 2014, Dr. Kaitin has held a primary appointment as Professor of Public Health and Community Medicine at the Tufts University School of Medicine, as well as secondary appointments as Professor of Medicine and Professor of Integrative Physiology and Pathobiology at Tufts University School of Medicine. In December 2014, he received the appointment of Advisory Professor at Shanghai Medical College of Fudan University. Dr. Kaitin has served on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel since September 1999. At the Tufts University School of Medicine, Dr. Kaitin was a Research Associate Professor of Medicine from October 2003 to May 2008 and a Research Professor from May 2008 to August 2014. He has written extensively on a broad range of drug development issues and has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform. In 2011, Dr. Kaitin received the Dr. Louis M. Sherwood Award granted by the Academy of Pharmaceutical Physicians and Investigators, in 2020, he was named a Global Fellow in Medicines Development by the International Federation of Pharmaceutical Physicians, and in 2021, he received the Distinguished Achievement Award from the Sino-American Pharmaceutical Professionals Association. Dr. Kaitin is a former Editor-in-Chief of the Drug Information Journal, and from 1997 to 1998 he was President of the Drug Information Association. He is currently Editor-in-Chief of Expert Review of Clinical Pharmacology, and he currently serves on the editorial boards of a number of peer-review journals. Dr. Kaitin serves as an expert consultant to the U.S. Department of Defense on Bioterror Countermeasure issues. He received a B.S. from Cornell University and an M.S. and Ph.D. in Pharmacology from the University of Rochester.

Committee:

Audit
Nominating and Governance
Compensation

---

Anne E. Borgman, M.D., has served on the Board since October 2022. She is Chief Medical Officer of Sutro Biopharma, Inc., and currently serves on the Board of Directors of NextCure, Inc. and NiKang Therapeutics, Inc. Dr. Borgman has extensive experience in all phases of oncology drug development of small molecules, antibodies and combinations at large and small companies across the biotech and pharmaceutical industries which includes nine regulatory approvals.  Previously, Dr. Borgman served as Vice President and Therapeutic Area Head of Oncology, Hematology, and Transplant Research and Development at Jazz Pharmaceuticals.  As Vice President of Research & Development at Exelixis Biopharmaceuticals, Inc., Dr. Borgman was the clinical lead responsible for global drug development in oncology for cabozantinib, a multi-targeted tyrosine kinase inhibitor.  She was Associate Chief Medical Officer at KaloBios Pharmaceuticals, and Vice President and Chief Medical Officer at Talon Therapeutics (formerly Hana Biosciences). Dr. Borgman held various medical director roles at Abbott Laboratories including Global Project Head of Oncology, where she created the early development strategies for venetoclax and veliparib.

Dr. Borgman received a B.S. in biochemistry from University of Illinois, Urbana-Champaign and her M.D. from Loyola University Chicago Stritch School of Medicine.  She completed her residency in pediatrics at the Baylor College of Medicine in Houston, Texas, and her fellowship in pediatric hematology-oncology and bone marrow transplantation at the David Geffen School of Medicine at UCLA. Dr. Borgman is a graduate of the Stanford Executive Program and an alumni of Stanford University’s Graduate School of Business.

Committee:

Nominating and Governance

---

Marc Rubin, M.D., has served on the Board since June 2010. Dr. Rubin was President and Chief Executive Officer of Titan Pharmaceuticals from October 2007 to December 2008, Executive Chairman of the Board of Directors from May 2009 to August 2022, and a member of the Board from August 2022 to September 2023. From June 2006 until February 2007, he served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Beginning in October 2003 and until the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG with responsibility for global development and for three global business units, including the oncology business unit, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, he held positions in global clinical and commercial development at GlaxoSmithKline, where he oversaw programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, Dr. Rubin was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. He holds an M.D. from Cornell University Medical College.

Committee:

Audit
Compensation

---

Mr. Dentzer is Chief Executive Officer and a member of the Board of Directors of Curis. Mr. Dentzer joined Curis in 2016 and was named CEO in 2018. Prior to joining Curis, Mr. Dentzer held senior leadership positions with Dicerna, Amicus, and Biogen. Mr. Dentzer holds a B.A. in Philosophy from Boston College and an M.B.A. from the University of Chicago. In 2021, Mr. Dentzer was named a Top 25 CEO in Biotech by The Healthcare Technology Report and currently serves on the Board of Directors of Imunon.

---